BridgeBio Pharma (BBIO) Long-Term Investments (2018 - 2026)

BridgeBio Pharma has reported Long-Term Investments for 7 years, with the latest figure at $61.5 million in Q1 2026.

• Quarterly Long-Term Investments fell 52.0% year-over-year to $61.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.5 million (down 52.0% YoY) and the FY2025 annual result came in at $80.0 million, down 44.37% from the prior year.
• Long-Term Investments slipped to $61.5 million in Q1 2026 per BBIO's latest filing, from $80.0 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $160.4 million in Q3 2024 and troughed at $61.5 million in Q1 2026.
• A 3-year average of $111.4 million and a median of $112.5 million in 2024 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2025 and 2026: Long-Term Investments dropped 7.7% in 2025, then plunged 52.0% in 2026.
• Over 3 years, Long-Term Investments stood at $143.7 million in 2024, then plunged by 44.37% to $80.0 million in 2025, then declined by 23.06% to $61.5 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $61.5 million, $80.0 million, and $92.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.